Even after discontinuation of therapy, extended follow-up is recommended to detect delayed-onset ICI-DM.[15] Current management predominantly relies on insulin therapy, whereas corticosteroids are contraindicated because they tend to exacerbate hyperglycemia without proven clinical benefits.[1] For patients with mild symptoms and well-controlled blood glucose levels (≤8.9 mmol/L), ICIs treatment may cautiously continue under rigorous monitoring. Here, INS is linked to Hyperglycemia.